Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
None
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or foscarnet 40 mg/kg every 8 hours or 60 mg/kg

vasectomy
famciclovir
copper
tingling
HIV Infection
  • 15431 views
  • 19 Jan, 2022
  • 20 locations
None
CMV-TCR-T Cells for Refractory CMV Infection After HSCT

This is a single centre, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating refractory CMV infection after HSCT.

  • 0 views
  • 29 Oct, 2021
  • 1 location
None
Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection

The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments.

antiviral drugs
antiviral treatment
estimated creatinine clearance
ganciclovir
letermovir
  • 0 views
  • 12 Aug, 2021
  • 1 location
None
AntiCMV mol cules Monitoring in Real-life in Stem Cell Recipients

prophylaxis in France. Foscarnet, iv-administered and nephrotoxic, remains less used. There is thus a high expectation from less toxic molecules for prophylaxis The development letermovir recently available

  • 0 views
  • 27 Jan, 2021
  • 1 location